Publicaciones en colaboración con investigadoras/es de Hospital de Cruces (21)

2019

  1. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

    Radiotherapy and Oncology, Vol. 135, pp. 13-18

2018

  1. Analysis of predictors of pain response in patients with bone metastasis undergoing palliative radiotherapy: Does age matter?

    Journal of Medical Imaging and Radiation Oncology, Vol. 62, Núm. 4, pp. 578-584

2017

  1. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma

    Clinical and Translational Oncology, Vol. 19, Núm. 11, pp. 1337-1349

  2. Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision

    Brachytherapy, Vol. 16, Núm. 1, pp. 201-206

2016

  1. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial

    Radiotherapy and Oncology, Vol. 119, Núm. 1, pp. 91-96

  2. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy

    Journal of Contemporary Brachytherapy, Vol. 8, Núm. 6, pp. 477-483

2015

  1. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, Núm. 9, pp. 1378-1389

2014

  1. A prospective analysis of factors that influence weight loss in patients undergoing radiotherapy

    Chinese Journal of Cancer, Vol. 33, Núm. 4, pp. 204-210

  2. A prospective analysis of inter- and intrafractional errors to calculate CTV to PTV margins in head and neck patients

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 113-120

  3. Do patients with head and neck human papillomavirus-related carcinoma need a different treatment approach?

    International Journal of Clinical Oncology

  4. Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy

    Journal of Contemporary Brachytherapy, Vol. 6, Núm. 2, pp. 154-160

  5. Stereotactic body radiotherapy: An attractive treatment modality for recurrent head and neck carcinoma. (Regarding Lartigau et al.: Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer)

    Radiotherapy and Oncology

  6. The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach

    Cancer Treatment Reviews, Vol. 40, Núm. 1, pp. 178-189

2013

  1. Definitive radiotherapy for T1 glottic squamous cell carcinoma: A 15-year Cruces University Hospital experience

    Clinical and Translational Oncology, Vol. 15, Núm. 11, pp. 925-931

2012

  1. An infrared microspectroscopy 2DCOS study of the effect of radiation on normal and cancer cells

    Vibrational Spectroscopy, Vol. 60, pp. 189-192

  2. Detection of risk factors that influence weight loss in patients undergoing radiotherapy

    Reports of Practical Oncology and Radiotherapy, Vol. 17, Núm. 5, pp. 269-275

  3. Patterns of care for brachytherapy in Europe: Updated results for Spain

    Clinical and Translational Oncology, Vol. 14, Núm. 1, pp. 36-42

  4. Smartphones and tablets: Reshaping radiation oncologists' lives

    Reports of Practical Oncology and Radiotherapy, Vol. 17, Núm. 5, pp. 276-280

2008

  1. Patterns of Care for Brachytherapy in Europe: Facilities and resources in brachytherapy in the European area

    Brachytherapy, Vol. 7, Núm. 3, pp. 223-230

2002

  1. L-2-oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour efficacy of biochemotherapy in mice bearing B16 melanoma liver metastases

    Melanoma Research, Vol. 12, Núm. 1, pp. 17-26